Jin Kang Wang
Directeur Technique/Scientifique/R&D chez BIOMICS BIOPHARMA LTD
Profil
Jin Kang Wang is currently the Chief Science Officer & Vice President at Biomics Biotechnologies Co., Ltd.
since 2012.
He is also the Chief Scientific Officer at Biomics Biopharma Ltd.
since 2008.
Previously, he worked as a Senior Scientist at ALZA Corp., NeoPharm, Inc., Valentis, Inc., and Genteric, Inc. Dr. Wang holds a doctorate degree from Marquette University, which he obtained in 1990.
He also completed his undergraduate studies at Beijing Normal University.
Postes actifs de Jin Kang Wang
| Sociétés | Poste | Début |
|---|---|---|
| BIOMICS BIOPHARMA LTD | Directeur Technique/Scientifique/R&D | 01/01/2008 |
Biomics Biotechnologies Co., Ltd.
 Biomics Biotechnologies Co., Ltd. BiotechnologyHealth Technology Biomics Biotechnologies Co., Ltd. develops ribonucleic acid interference based treatment products. Its products offer treatments for Age-related Macular Degeneration (AMD), Hepatitis B, bladder cancer, and other diseases. The company was founded by York Yuan Zhu on February 17, 2006 and is headquartered in Nantong, China. | Directeur Technique/Scientifique/R&D | 01/01/2008 |
Anciens postes connus de Jin Kang Wang
| Sociétés | Poste | Fin |
|---|---|---|
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Directeur Technique/Scientifique/R&D | - |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Directeur Technique/Scientifique/R&D | - |
Genteric, Inc.
 Genteric, Inc. Pharmaceuticals: MajorHealth Technology Genteric, Inc. develops revolutionary therapeutic protein delivery technology. It is a biotech company formed to commercialize several proprietary technology platforms that harness the body's own protein production and distribution system. Genteric proprietary technology captures natural protein manufacturing capability for therapeutic benefit. The company is headquartered in Redwood City, CA. | Directeur Technique/Scientifique/R&D | - |
| ALZA CORPORATION | Directeur Technique/Scientifique/R&D | - |
Formation de Jin Kang Wang
| Beijing Normal University | Undergraduate Degree |
| Marquette University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOMICS BIOPHARMA LTD | Process Industries |
| Entreprise privées | 5 |
|---|---|
Biomics Biotechnologies Co., Ltd.
Biomics Biotechnologies Co., Ltd. BiotechnologyHealth Technology Biomics Biotechnologies Co., Ltd. develops ribonucleic acid interference based treatment products. Its products offer treatments for Age-related Macular Degeneration (AMD), Hepatitis B, bladder cancer, and other diseases. The company was founded by York Yuan Zhu on February 17, 2006 and is headquartered in Nantong, China. | Health Technology |
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
Genteric, Inc.
Genteric, Inc. Pharmaceuticals: MajorHealth Technology Genteric, Inc. develops revolutionary therapeutic protein delivery technology. It is a biotech company formed to commercialize several proprietary technology platforms that harness the body's own protein production and distribution system. Genteric proprietary technology captures natural protein manufacturing capability for therapeutic benefit. The company is headquartered in Redwood City, CA. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
